{{Rsnum
|rsid=1004982
|Gene=CYP19A1
|Chromosome=15
|position=51321614
|Orientation=minus
|GMAF=0.4073
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CYP19A1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 33.6 | 49.6 | 16.8
| HCB | 45.3 | 43.8 | 10.9
| JPT | 46.0 | 44.2 | 9.7
| YRI | 23.1 | 44.2 | 32.7
| ASW | 29.8 | 52.6 | 17.5
| CHB | 45.3 | 43.8 | 10.9
| CHD | 53.2 | 38.5 | 8.3
| GIH | 46.5 | 42.6 | 10.9
| LWK | 25.5 | 52.7 | 21.8
| MEX | 25.9 | 51.7 | 22.4
| MKK | 14.1 | 50.6 | 35.3
| TSI | 34.3 | 45.1 | 20.6
| HapMapRevision=28
}}{{PMID|19064562|OA=1
}} increased risk of [[breast cancer]] with concurrent proliferative fibrocystic conditions
*[[rs1004982]](C) 2.19 (1.24-3.85)
*[[rs28566535]](C) 2.20 (1.27-3.82)
*[[rs936306]](T) 1.94 (1.13-3.30) 
*[[rs4775936]](C) 1.95 (1.07-3.58)

{{PMID Auto
|PMID=18636124
|Title=Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}